Editorial Board

Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Source Type: research

Related Links:

Conditions:   B-cell Acute Lymphoblastic Leukemia;   Lymphoma;   Myeloid Leukemia;   Multiple Myeloma;   Hepatoma;   Gastric Cancer;   Pancreatic Cancer;   Mesothelioma;   Colorectal Cancer;   Esophagus Cancer;   Lung Cancer;   Glioma;   Melanoma;   Synovial Sarcoma;   Ovarian Cancer ;   Renal Carcinoma Intervention:   Biological: CAR-T cell immunotherapy Sponsors:   Shenzhen BinDeBio Ltd.;   The First Affiliated Hospital of Zhengzhou University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 18 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Jacqueline C. Barrientos, Susan O'Brien, Jennifer R. Brown, Neil E. Kay, Nishitha M. Reddy, Steven Coutre, Constantine Tam, Stephen Mulligan, Ulrich Jaeger, Stephen Devereux, Christopher Pocock, Tadeusz Robak, Stephen J. Schuster, Anna Schuh, Devinder Gill, Adrian Bloor, Claire Dearden, Carol Moreno, Gavin Cull, Mike HamblinAbstractBackgroundIbrutinib compared with ofatumumab significantly improves progression-free and overall survival in patients with previously treated chronic lymphocytic leukemia/small lymphocytic l...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
AbstractIt is well established that some rheumatic syndromes (RS) are associated with several hematological malignancies. We aimed to describe the clinical course of patients with hematological malignancies mimicking RS. We studied a series of four patients presenting with apparent RS who were eventually diagnosed with hematological malignancies, and reviewed the relevant literature. Our series consisted of 4 patients, with a mean age of 62.8  ± 20.3 years, who presented to our rheumatology unit between December 2012 and March 2018. Two patients were initially diagnosed with polyarthritis. One of these...
Source: Rheumatology International - Category: Rheumatology Source Type: research
In the phase III study RESONATETM, ibrutinib reduced the risk of progression and improved overall survival vs ofatumumab in previously treated patients with CLL/SLL. In this novel analysis of patient well-being including patient-reported outcomes, ibrutinib reduced disease burden while preserving parameters of hematologic and immunologic function in RESONATE. These results suggest that ibrutinib can improve QoL while prolonging survival.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Publication date: September 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 9Author(s):
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: September 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 9Author(s):
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Source Type: research
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Source Type: research
ConclusionsOur study revealed aberrant genetic aberrations in signaling networks that may contribute to race-specific aspects of leukemogenesis. Our results suggest the value of WES as a tool for development of individual gene signatures and gene scores for AA and EA children afflicted by B-ALL. These findings may ultimately impact disease management and contribute to the elimination of disparate outcomes in AA children with B-ALL.Graphical abstract
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionWe did not observe cardiotoxicity from bortezomib-based chemotherapy despite very intensive evaluation with multiple modalities. There was neither cumulative nor transient alterations in our metrics, suggesting that bortezomib is safe from a cardiovascular standpoint in patients free of cardiovascular disease.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Hematology | Leukemia | Lymphoma | Myeloma